NCCN Guidelines® Insights: Rectal cancer, version 3.2024 Featured updates to the NCCN Guidelines Guidelines

  


Authors: Benson, A. B.; Venook, A. P.; Adam, M.; Chang, G.; Chen, Y. J.; Ciombor, K. K.; Cohen, S. A.; Cooper, H. S.; Deming, D.; Garrido-Laguna, I.; Grem, J. L.; Haste, P.; Hecht, J. R.; Hoffe, S.; Hunt, S.; Hussan, H.; Johung, K. L.; Joseph, N.; Kirilcuk, N.; Krishnamurthi, S.; Malla, M.; Maratt, J. K.; Messersmith, W. A.; Meyerhardt, J.; Miller, E. D.; Mulcahy, M. F.; Nurkin, S.; Parikh, A.; Patel, H.; Pedersen, K.; Saltz, L.; Schneider, C.; Shibata, D.; Shogan, B.; Skibber, J. M.; Sofocleous, C. T.; Tavakkoli, A.; Willett, C. G.; Wu, C.; Jones, F.; Gurski, L.
Title: NCCN Guidelines® Insights: Rectal cancer, version 3.2024 Featured updates to the NCCN Guidelines
Abstract: The determination of an optimal treatment plan for an individual patient with rectal cancer is a complex process. In addition to decisions relating to the intent of rectal cancer surgery (ie, curative or palliative), consideration must also be given to the likely functional results of treatment, including the probability of maintaining or restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly for patients with distal rectal cancer, finding a balance between curative-intent therapy while having minimal impact on quality of life can be challenging. Furthermore, the risk of pelvic recurrence is higher in patients with rectal cancer compared with those with colon cancer, and locally recurrent rectal cancer is associated with a poor prognosis. Careful patient selection and the use of sequenced multimodality therapy following a multidisciplinary approach is recommended. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a “watch-and-wait” nonoperative management approach for clinical complete responders to neoadjuvant therapy. © JNCCN—Journal of the National Comprehensive Cancer Network.
Keywords: controlled study; cancer surgery; treatment failure; major clinical study; multimodality cancer therapy; united states; cancer radiotherapy; disease free survival; combined modality therapy; neoadjuvant therapy; cancer staging; follow up; neoplasm staging; colorectal cancer; quality of life; prevalence; cohort analysis; practice guideline; pathology; oncology; diagnosis; medical oncology; minimally invasive surgery; preoperative treatment; clinical practice guideline; rectal neoplasms; rectum cancer; rectum tumor; therapy; total mesorectal excision; en bloc resection; secondary analysis; pathological complete response; endoscopic mucosal resection; local excision; transanal endoscopic microsurgery; procedures; endoscopic submucosal dissection; metastasis free survival; humans; human; article; short-course radiotherapy; multidisciplinary team
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 22
Issue: 6
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2024-08-01
Start Page: 366
End Page: 375
Language: English
DOI: 10.6004/jnccn.2024.0041
PUBMED: 39151454
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201581961&doi=10.6004%2fjnccn.2024.0041&partnerID=40&md5=208f8c7fe8b9e6d0f51013bb047d2ad0
Notes: Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Leonard B Saltz
    791 Saltz
  2. Constantinos T Sofocleous
    245 Sofocleous
Related MSK Work